• Vaccine Name: ALVAC-P53 Vaccine
• Target Pathogen: Cancer
• Target Disease: Cancer
• Vaccine Ontology ID: VO_0004739
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• Antigen: p53
• human TP53 (P53) gene engineering:
  • Type: Recombinant vector construction
  • Description: Several canarypox virus recombinants expressing human or murine p53 in wild-type or mutant form were constructed (Roth et al., 1996).
  • Detailed Gene Information: Click Here.
• Vector:
  • Vector name:
  • VO vector ID: VO_0001043
• Preparation: Several canarypox virus recombinants expressing human or murine p53 in wild-type or mutant form were constructed (Roth et al., 1996).
• Immunization Route: Intramuscular injection (i.m.)
• Description: Potent T-cell and IgG antibody responses against the vector component of the ALVAC vaccine were induced in the majority of the colorectal cancer patients. Enzyme-linked immunosorbent-spot assay (ELISPOT) analysis of vaccine-induced immunity revealed the presence of IFN-gamma-secreting T cells against both ALVAC and p53, whereas no significant interleukin-4 responses were detected. Vaccine-mediated enhancement of p53-specific T-cell immunity was found in two patients in the highest-vaccine-dose group.(van et al., 2002)

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Mice were immunized with the viruses constructed (Roth et al., 1996).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: Mice were challenged with an isogenic and highly tumorigenic mouse fibroblast tumor cell line expressing high levels of mutant p53 (Roth et al., 1996).
• Efficacy: The tumor protection was equally effective regardless of whether wild-type or mutant p53 was used for the immunization, indicating that the immunologic response was not dependent on any particular p53 mutation and that immunization with this live virus vaccine works effectively against mutant p53 protein expressed in a tumor cell (Roth et al., 1996).